A team of international scientists led by the Medical University of Vienna has discovered a link between the biological mechanisms of diabetes and prostate cancer.
Their findings, published in Molecular Cancer, reveal that a protein called PPARγ, which is crucial for regulating metabolic processes in diabetes, may also play a role in the growth of prostate cancer cells. This discovery suggests that certain diabetes medications might also be effective in treating prostate cancer.
PPARγ, short for peroxisome proliferator-activated receptor gamma, is a protein that acts as a transcription factor. This means it helps control how genes are activated, influencing processes like metabolism, inflammation, and cell growth.
For over two decades, PPARγ has been studied in diabetes research because it helps manage insulin sensitivity. Medications called thiazolidinediones, such as pioglitazone, specifically target PPARγ to improve blood sugar control in people with type 2 diabetes.
In recent years, cancer researchers have also started investigating PPARγ because of its role in cell growth and metabolism. Led by Lukas Kenner from the Clinical Department of Pathology at MedUni Vienna, the research team explored how PPARγ affects prostate cancer cells.
They studied cell cultures and tissue samples from patients to understand how different levels of PPARγ activity influence the growth of cancer cells.
The results were promising. The team found that pioglitazone, a common diabetes drug that targets PPARγ, seemed to reduce the growth and metabolic activity of prostate cancer cells.
They also observed that prostate cancer patients who had diabetes and were treated with PPARγ-targeting drugs did not experience cancer recurrence during the study’s observation period. This suggests that activating PPARγ with certain medications could help control prostate cancer growth.
Prostate cancer is the second most common cancer among men worldwide. Despite major advancements in medicine, it remains a leading cause of cancer deaths in men. In Austria alone, one in every eight cancer-related deaths in men is due to prostate cancer.
Current treatment options include surgery, radiation therapy, and medication. However, identifying new molecular pathways like the one involving PPARγ could lead to more targeted and effective treatments.
Lukas Kenner, the principal investigator, explained that the findings open up new possibilities for prostate cancer therapy. The idea is that existing diabetes drugs could potentially be repurposed to slow down or even stop the growth of prostate cancer cells.
This approach could complement current treatments, offering hope for patients who are resistant to conventional therapies.
The research team now plans to conduct further studies to explore how PPARγ influences tumor growth and to test the effectiveness of PPARγ-targeting drugs in clinical trials. If successful, this could lead to new treatment strategies that are both affordable and accessible, given that these diabetes medications are already approved and widely available.
The discovery of PPARγ’s role in prostate cancer is significant because it bridges the gap between two major health conditions—diabetes and cancer.
It also highlights how understanding molecular processes can lead to unexpected breakthroughs in treatment. With more research, this connection could change the way prostate cancer is managed, providing new hope for patients worldwide.
If you care about prostate cancer, please read studies about a natural ally against prostate cancer, and supplements and keto diet can boost immunotherapy for prostate cancer.
For more health information, please see recent studies about how to harness the power of anti-cancer foods and supplements, and low-fat diet may help stop cancer growth.
The research findings can be found in Molecular Cancer.
Copyright © 2025 Knowridge Science Report. All rights reserved.
